Good news for Abbvie....
Vertex Pharmaceuticals said the Food and Drug Administration put a partial clinical hold on a midstage study of its experimental hepatitis C treatment VX-135 because of toxicity concerns.
Vertex shares fell 9.1% to $79.66 in after-hours trading.
Vertex Pharmaceuticals said the Food and Drug Administration put a partial clinical hold on a midstage study of its experimental hepatitis C treatment VX-135 because of toxicity concerns.
Vertex shares fell 9.1% to $79.66 in after-hours trading.